Persephoni Backs SelSym to Advance Trauma Bleeding Care
RESEARCH TRIANGLE PARK, N.C., July 15, 2026 Persephoni BioSciences has announced a strategic investment in SelSym Biotech, bringing the...
Genentech
Advertisement
Genentech Wins FDA Priority Review for Gazyva in pMN
SOUTH SAN FRANCISCO, Calif., July 14, 2026 Genentech, a member of the Roche Group, has received U.S. Food and...
Astex and Genentech Partner to Advance Breast Cancer Drugs
CAMBRIDGE, United Kingdom, July 6, 2026 Astex Pharmaceuticals has entered into an exclusive worldwide research collaboration and license agreement...
Genentech Wins FDA Priority Review for Enspryng in Thyroid Eye Disease
SOUTH SAN FRANCISCO, Calif., June 29, 2026 Genentech, a member of the Roche Group, announced that the U.S. Food...
Roche Secures FDA sBLA Acceptance for Lunsumio VELO Combination
BASEL, Switzerland, June 18, 2026 Roche announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental...
Advertisements
Roche’s Giredestrant NDA Accepted by FDA for Early Breast Cancer
BASEL, Switzerland, June 2, 2026 Roche announced that the U.S. Food and Drug Administration (FDA) has accepted the New...
FDA Accepts Genentech NDA for Giredestrant in Early Breast Cancer
SOUTH SAN FRANCISCO, Calif., June 1, 2026 Genentech announced that the U.S. Food and Drug Administration (FDA) has accepted...
Genentech Advances Obesity Portfolio with New ADA 2026 Data
SOUTH SAN FRANCISCO, Calif., May 31, 2026 Genentech, a member of the Roche Group, announced that new clinical data...
Genentech Highlights Giredestrant Data at ASCO 2026
SOUTH SAN FRANCISCO, Calif., May 18, 2026 Genentech, a member of the Roche Group, announced that it will present...
Genentech Reports Strong Phase 3 Enspryng Data in MOGAD
South San Francisco, California, USA – April 21, 2026 In a major breakthrough for rare neurological diseases, Genentech has...
Advertisement
